Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Taras Yurchenko

Physician Assistant, Medical Dover, DE Physician Assistant

NPI 1912559782 CMS profile 10911527

1100 Forrest Ave, Dover, DE 19904

Open in the dashboard

General payments

$7,707

354 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Taras Yurchenko of Dover, DE is reported in the CMS Open Payments database as having received $7,707 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,709 118
2024 General $1,814 84
2023 General $1,382 64
2022 General $1,120 54
2021 General $681 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Taras Yurchenko
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Taras Yurchenko were reported at $2,709. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Taras Yurchenko Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $681 $156 $41–$563 $132
2022 $1,120 $185 $55–$649 $149
2023 $1,382 $199 $58–$717 $160
2024 $1,814 $206 $62–$740 $164
2025 $2,709 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,549 81 payments
  2. Janssen Biotech, Inc. $1,244 42 payments
  3. UCB, Inc. $1,044 51 payments
  4. Novartis Pharmaceuticals Corporation $690 31 payments
  5. Amgen Inc. $473 24 payments
  6. Mallinckrodt Hospital Products Inc. $415 15 payments
  7. GlaxoSmithKline, LLC. $407 14 payments
  8. Radius Health, Inc. $307 13 payments
  9. Lilly USA, LLC $298 16 payments
  10. Pfizer Inc. $179 12 payments
  11. Other $1,099 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,423 350 payments
  2. Education $284 4 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,089 35 payments
  2. RINVOQ $888 44 payments
  3. Bimzelx $614 28 payments
  4. Cimzia $431 23 payments
  5. COSENTYX $430 21 payments
  6. ACTHAR $415 15 payments
  7. BENLYSTA $407 14 payments
  8. SIMPONI ARIA $406 19 payments
  9. SKYRIZI Immunology $383 21 payments
  10. SKYRIZI Immunology $258 15 payments
  11. Other $3,103 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,396

Median for Physician Assistant: 241

Drug cost

$1,477,138

Median for Physician Assistant: $4,110

Branded share of claims

22.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready Pen Secukinumab Brand 25 $359,494
Humira(Cf) Pen Adalimumab Brand 31 $286,350
Enbrel Sureclick Etanercept Brand 23 $253,671
Remicade Infliximab Brand 24 $219,215
Taltz Autoinjector Ixekizumab Brand 18 $122,183
Tymlos Abaloparatide Brand 24 $76,292
Orencia Clickject Abatacept Brand 12 $70,681
Teriparatide Generic 12 $57,752
Hydroxychloroquine Sulfate Generic 222 $12,538
Methotrexate Methotrexate Sodium Brand 138 $3,527

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$1,544,785

Of which drugs: $1,433,946

Medicare patients

505

Average age 74

Services billed

85,446

423 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Osteoporosis 60%
Diabetes 30%
Ischemic heart disease 27%
Chronic kidney disease 25%
Depression 23%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 191 18,240 $370,467
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 15 10,550 $350,214
Injection, golimumab, 1 mg, for intravenous use J1602 Office 11 7,850 $66,637
Injection, romosozumab-aqqg, 1 mg J3111 Office 12 5,670 $48,597
Injection, zoledronic acid, 1 mg J3489 Office 18 90 $409
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 430 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $207
$207 — —
Bimzelx
  • UCB, Inc. $192
$192 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $183
$183 25 —
RINVOQ
  • AbbVie, Inc. $168
$168 — —
SKYRIZI
  • AbbVie, Inc. $155
$155 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record